Login to Your Account

ISTA’s Stock Slides On Vitrase Missed Primary Endpoint

By Kim Coghill

Wednesday, March 27, 2002
Wall Street did not look kindly on ISTA Pharmaceuticals’ failure to meet its primary endpoint in two pivotal Phase III studies of Vitrase, a single injection for treating vitreous hemorrhage. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription